PRRT2 and malignant colon neoplasm: Moreover, fidarestat, an AKR1B1 inhibitor, decreased COX2 and NF-κB on HT29 colon cancer cells and inhibited PKC, AKT and COX2 in azoxymethane-induced colonic premalignant mice [45].